Valid for Submission
C54.8 is a billable diagnosis code used to specify a medical diagnosis of malignant neoplasm of overlapping sites of corpus uteri. The code C54.8 is valid during the fiscal year 2022 from October 01, 2021 through September 30, 2022 for the submission of HIPAA-covered transactions.
The ICD-10-CM code C54.8 might also be used to specify conditions or terms like overlapping malignant neoplasm of body of uterus.
The code C54.8 is applicable to female patients only. It is clinically and virtually impossible to use this code on a non-female patient.
The following anatomical sites found in the Table of Neoplasms apply to this code given the correct histological behavior: corpus overlapping sites or uterus, uteri, uterine overlapping sites .
The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10 Code Edits are applicable to this code:
The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:
- Overlapping malignant neoplasm of body of uterus
Diagnostic Related Groups - MS-DRG Mapping
|MS-DRG||MS-DRG Title||MCD||Relative Weight|
|736||UTERINE AND ADNEXA PROCEDURES FOR OVARIAN OR ADNEXAL MALIGNANCY WITH MCC||13||4.2582|
|737||UTERINE AND ADNEXA PROCEDURES FOR OVARIAN OR ADNEXAL MALIGNANCY WITH CC||13||2.0582|
|738||UTERINE AND ADNEXA PROCEDURES FOR OVARIAN OR ADNEXAL MALIGNANCY WITHOUT CC/MCC||13||1.4766|
|739||UTERINE AND ADNEXA PROCEDURES FOR NON-OVARIAN AND NON-ADNEXAL MALIGNANCY WITH MCC||13||3.8217|
|740||UTERINE AND ADNEXA PROCEDURES FOR NON-OVARIAN AND NON-ADNEXAL MALIGNANCY WITH CC||13||1.8|
|741||UTERINE AND ADNEXA PROCEDURES FOR NON-OVARIAN AND NON-ADNEXAL MALIGNANCY WITHOUT CC/MCC||13||1.2795|
The relative weight of a diagnostic related group determines the reimbursement rate based on the severity of a patient's illness and the associated cost of care during hospitalization.
Convert C54.8 to ICD-9 Code
Table of Neoplasms
The code C54.8 is included in the table of neoplasms by anatomical site. For each site there are six possible code numbers according to whether the neoplasm in question is malignant, benign, in situ, of uncertain behavior, or of unspecified nature. The description of the neoplasm will often indicate which of the six columns is appropriate.
Where such descriptors are not present, the remainder of the Index should be consulted where guidance is given to the appropriate column for each morphological (histological) variety listed. However, the guidance in the Index can be overridden if one of the descriptors mentioned above is present.
|»uterus, uteri, uterine|
Information for Patients
The uterus, or womb, is the place where a baby grows when a women is pregnant. There are different types of uterine cancer. The most common type starts in the endometrium, the lining of the uterus. This type is also called endometrial cancer.
The symptoms of uterine cancer include
- Abnormal vaginal bleeding or discharge
- Trouble urinating
- Pelvic pain
- Pain during intercourse
Uterine cancer usually happens after menopause. It is more common in women who have obesity. You also have a higher risk if you took estrogen-only hormone replacement therapy (menopausal hormone therapy) for many years.
Tests to find uterine cancer include a pelvic exam, imaging tests, and a biopsy. The most common treatment is a hysterectomy, which is surgery to remove the uterus. Sometimes the surgery also removes the ovaries and fallopian tubes. Other treatments include hormone therapy, radiation therapy, and chemotherapy. Some women get more than one type of treatment.
NIH: National Cancer Institute
[Learn More in MedlinePlus]